A2 Biotherapeutics
PrivateLast Round
Grant
May 6, 2025
Total Funding Raised
$270.8M
Company Overview
A2 Biotherapeutics is a biotechnology company that develops logic-gated cell therapies for the treatment of solid tumors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
A2 Biotherapeutics Comparables
Compare A2 Biotherapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| ArsenalBio | 89% | |
| Eureka Therapeutics | 82% | |
| Link Cell Therapies | 82% |
A2 Biotherapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | May 6, 2025 | ||||
| Series C | Jan 9, 2025 | ||||
| Series B Extension | Dec 19, 2022 | ||||
| Series B | Oct 6, 2020 | ||||
| Series A Extension | Nov 5, 2019 |
Key People
Founding team and executive leadership
A2 Biotherapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| The Column Group | Series B, Series A Extension, Series C |
| Perceptive Advisors | Series C |
| Vida Ventures | Series B, Series C, Series A Extension |
| Aisling Capital | Series C |
| Casdin Capital | Series B |
| Nextech Invest | Series B, Series A Extension |
| UC Investments | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 23, 2026
Three abstracts accepted for presentation at the 2026 ASCO Annual Meeting.
- Oct 3, 2025
Four abstracts accepted for the Society for Immunotherapy of Cancer meeting.
Recent news
Latest coverage and updates
- attends_eventSep 15, 2026
A2 Biotherapeutics, Inc. attends event 2026 Cell Coast Conference.
A2 Biotherapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about A2 Biotherapeutics's valuation, stock price, and market status.
Is A2 Biotherapeutics a public or private company?
A2 Biotherapeutics is a private company.
What is the current stock price of A2 Biotherapeutics?
A2 Biotherapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is A2 Biotherapeutics worth (valuation)?
Valuation information for A2 Biotherapeutics is not publicly available.
Can I buy A2 Biotherapeutics stock?
A2 Biotherapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was A2 Biotherapeutics's last funding round?
A2 Biotherapeutics's most recent funding round was Grant on May 6, 2025.
Who are the main investors in A2 Biotherapeutics?
Key investors in A2 Biotherapeutics include The Column Group, Vida Ventures, Casdin Capital, Nextech Invest, Samsara BioCapital.
Will A2 Biotherapeutics IPO soon?
No public IPO plans have been announced for A2 Biotherapeutics.
How can I track A2 Biotherapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor A2 Biotherapeutics's secondary market activity and sign up for updates.